Alpha emitter radium 223 in high-risk osteosarcoma: First clinical evidence of response and blood-brain barrier penetration

Vivek Subbiah; Pete Anderson; Eric Rohren

doi:10.1001/jamaoncol.2014.289

Alpha emitter radium 223 in high-risk osteosarcoma: First clinical evidence of response and blood-brain barrier penetration

Vivek Subbiah, Pete Anderson, Eric Rohren

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	253-255
Number of pages	3
Journal	JAMA Oncology
Volume	1
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2014.289
State	Published - May 1 2015

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2014.289

Cite this

@article{930ef8c6a30745178f6ed5e6b5b890f3,

title = "Alpha emitter radium 223 in high-risk osteosarcoma: First clinical evidence of response and blood-brain barrier penetration",

author = "Vivek Subbiah and Pete Anderson and Eric Rohren",

note = "Funding Information: Funding/Support: This research was supported the Shannon Wilkes Foundation; The University of Texas MD Anderson Cancer Center; and grant CA016672 from the National Institutes of Health. Bayer AG donated the radioactive isotopes. Funding Information: This research was supported the Shannon Wilkes Foundation; The University of Texas MD Anderson Cancer Center; and grant CA016672 from the National Institutes of Health. Bayer AG donated the radioactive isotopes. We thank Eugenie Kleinerman, MD, for her support for this study.",

year = "2015",

month = may,

day = "1",

doi = "10.1001/jamaoncol.2014.289",

language = "English (US)",

volume = "1",

pages = "253--255",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Alpha emitter radium 223 in high-risk osteosarcoma

T2 - First clinical evidence of response and blood-brain barrier penetration

AU - Subbiah, Vivek

AU - Anderson, Pete

AU - Rohren, Eric

N1 - Funding Information: Funding/Support: This research was supported the Shannon Wilkes Foundation; The University of Texas MD Anderson Cancer Center; and grant CA016672 from the National Institutes of Health. Bayer AG donated the radioactive isotopes. Funding Information: This research was supported the Shannon Wilkes Foundation; The University of Texas MD Anderson Cancer Center; and grant CA016672 from the National Institutes of Health. Bayer AG donated the radioactive isotopes. We thank Eugenie Kleinerman, MD, for her support for this study.

PY - 2015/5/1

Y1 - 2015/5/1

UR - http://www.scopus.com/inward/record.url?scp=84965092181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965092181&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2014.289

DO - 10.1001/jamaoncol.2014.289

M3 - Letter

C2 - 26181034

AN - SCOPUS:84965092181

SN - 2374-2437

VL - 1

SP - 253

EP - 255

JO - JAMA Oncology

JF - JAMA Oncology

IS - 2

ER -

Alpha emitter radium 223 in high-risk osteosarcoma: First clinical evidence of response and blood-brain barrier penetration

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this